- Home
- TNGX vs NEWT Comparison
TNGX vs NEWT Comparison
Compare TNGX & NEWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- NEWT
- Stock Information
- Founded
- TNGX 2014
- NEWT 1998
- Country
- TNGX United States
- NEWT United States
- Employees
- TNGX N/A
- NEWT N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- NEWT Major Banks
- Sector
- TNGX Health Care
- NEWT Finance
- Exchange
- TNGX Nasdaq
- NEWT Nasdaq
- Market Cap
- TNGX 351.2M
- NEWT 306.7M
- IPO Year
- TNGX N/A
- NEWT N/A
- Fundamental
- Price
- TNGX $5.16
- NEWT $10.40
- Analyst Decision
- TNGX Strong Buy
- NEWT Hold
- Analyst Count
- TNGX 6
- NEWT 4
- Target Price
- TNGX $12.20
- NEWT $14.00
- AVG Volume (30 Days)
- TNGX 3.9M
- NEWT 197.1K
- Earning Date
- TNGX 08-06-2025
- NEWT 07-28-2025
- Dividend Yield
- TNGX N/A
- NEWT 7.32%
- EPS Growth
- TNGX N/A
- NEWT 27.62
- EPS
- TNGX N/A
- NEWT 1.92
- Revenue
- TNGX $40,990,000.00
- NEWT $352,584,000.00
- Revenue This Year
- TNGX N/A
- NEWT N/A
- Revenue Next Year
- TNGX N/A
- NEWT $13.51
- P/E Ratio
- TNGX N/A
- NEWT $5.39
- Revenue Growth
- TNGX 10.09
- NEWT 23.06
- 52 Week Low
- TNGX $1.03
- NEWT $9.12
- 52 Week High
- TNGX $12.02
- NEWT $15.49
- Technical
- Relative Strength Index (RSI)
- TNGX 79.99
- NEWT 45.56
- Support Level
- TNGX $4.40
- NEWT $10.25
- Resistance Level
- TNGX $5.37
- NEWT $11.34
- Average True Range (ATR)
- TNGX 0.65
- NEWT 0.31
- MACD
- TNGX 0.10
- NEWT -0.05
- Stochastic Oscillator
- TNGX 93.68
- NEWT 25.23
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.